Valeant Pharmaceuticals (VRX) Announces U.S. Launch of Zelapar
Up)
Valeant Pharmaceuticals International (NYSE: VRX) announced the U.S. launch of Zelapar Orally Disintegrating Tablets. Zelapar is the first Parkinson's disease treatment to use a novel oral delivery system called Zydis(R) Technology, which allows the tablets to dissolve within seconds in the mouth and deliver more active drug at a lower dose. Zelapar will be available in pharmacies nationwide by July 19, 2006.
You May Also Be Interested In
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
